Drug Profile
KAND 145
Alternative Names: KAND-145Latest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator Kancera
- Class Anti-inflammatories; Antineoplastics; Small molecules
- Mechanism of Action Chemokine CXCL13 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Ovarian cancer
- Preclinical Chronic lymphocytic leukaemia
- No development reported Inflammation
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for preclinical development in Inflammation in Sweden (IV)
- 28 Mar 2024 No recent reports of development identified for preclinical development in Inflammation in Sweden (PO)
- 09 Nov 2023 Phase-I clinical trials in Ovarian cancer (In volunteers) in Finland (PO) (NCT06063343)